Related Experiment Videos
NMDA receptor hypofunction model of schizophrenia
J W Olney1, J W Newcomer, N B Farber
1Department of Psychiatry, Washington University, School of Medicine, St. Louis, MO 63110-1093, USA. olneyj@psychiatry.wustl.edu
Journal of Psychiatric Research
|January 11, 2000
Summary
Schizophrenia research shifts from dopamine hyperactivity to N-methyl-D-aspartate (NMDA) receptor hypofunction. This new hypothesis, based on NMDA antagonist drug effects, offers a promising avenue for understanding and treating schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Decades of dopamine hyperactivity hypothesis for schizophrenia yielded limited success.
- Emerging evidence suggests N-methyl-D-aspartate (NMDA) receptor hypofunction as a key factor.
- Phencyclidine (PCP) and related drugs' effects provide insights into NMDA receptor function.
Purpose of the Study:
- To present an updated NMDA receptor hypofunction hypothesis for schizophrenia.
- To explore the strengths and weaknesses of this hypothesis.
- To discuss therapeutic implications and future research directions.
Main Methods:
- Review of existing research on dopamine and NMDA receptor systems.
- Analysis of neurotoxic and psychotomimetic effects of NMDA antagonist drugs (e.g., PCP).
- Conceptual framework development based on experimental findings.
Main Results:
- The dopamine hyperactivity hypothesis has not adequately explained schizophrenia.
- NMDA receptor hypofunction offers a potentially more robust explanatory model.
- NMDA antagonist drugs produce psychosis-like symptoms, supporting the hypofunction hypothesis.
Conclusions:
- The NMDA receptor hypofunction hypothesis presents a promising alternative framework for schizophrenia.
- Further research is needed to validate this hypothesis and explore its therapeutic potential.
- Understanding NMDA receptor dysfunction could lead to novel treatment strategies for schizophrenia.